C4 Therapeutics Inc (CCCC) - Total Assets
Based on the latest financial reports, C4 Therapeutics Inc (CCCC) holds total assets worth $359.07 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See CCCC book value for net asset value and shareholders' equity analysis.
C4 Therapeutics Inc - Total Assets Trend (2018–2025)
This chart illustrates how C4 Therapeutics Inc's total assets have evolved over time, based on quarterly financial data.
C4 Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
C4 Therapeutics Inc's total assets of $359.07 Million consist of 71.9% current assets and 28.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.8% |
| Accounts Receivable | $2.40 Million | 0.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how C4 Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of C4 Therapeutics Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: C4 Therapeutics Inc's current assets represent 71.9% of total assets in 2025, a decrease from 84.3% in 2018.
- Cash Position: Cash and equivalents constituted 20.8% of total assets in 2025, down from 24.8% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 0.7% of total assets.
C4 Therapeutics Inc Competitors by Total Assets
Key competitors of C4 Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
C4 Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.81 | 5.71 | 8.55 |
| Quick Ratio | 7.81 | 5.71 | 8.55 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $225.08 Million | $212.59 Million | $284.36 Million |
C4 Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between C4 Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.07 |
| Latest Market Cap to Assets Ratio | 0.77 |
| Asset Growth Rate (YoY) | 2.7% |
| Total Assets | $359.07 Million |
| Market Capitalization | $276.15 Million USD |
Valuation Analysis
Below Book Valuation: The market values C4 Therapeutics Inc's assets below their book value (0.77x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: C4 Therapeutics Inc's assets grew by 2.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for C4 Therapeutics Inc (2018–2025)
The table below shows the annual total assets of C4 Therapeutics Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $359.07 Million | +2.71% |
| 2024-12-31 | $349.60 Million | -7.13% |
| 2023-12-31 | $376.45 Million | -12.62% |
| 2022-12-31 | $430.84 Million | -14.98% |
| 2021-12-31 | $506.76 Million | +26.65% |
| 2020-12-31 | $400.14 Million | +238.35% |
| 2019-12-31 | $118.26 Million | -19.27% |
| 2018-12-31 | $146.49 Million | -- |
About C4 Therapeutics Inc
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology p… Read more